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Take-home naloxone for opioid 
overdose in people who use drugs  
Advice for local authorities and local partners on promoting the wider 
availability of naloxone to reduce overdose deaths from heroin and similar 
drugs. 
The Advisory Council on the Misuse of Drugs (ACMD) recommended in 2012 that 
take-home naloxone should be made more widely available.1 It is also a 
recommendation of the World Health Organization.2 
Naloxone can be supplied to anyone: 
 currently using illicit opiates, such as heroin 
 receiving opioid substitution therapy 
 leaving prison with a history of drug use 
 who has previously used opiate drugs (to protect in the event of relapse) 
With the agreement of someone to whom naloxone can be supplied, it can also be 
provided to their family members, carers, peers and friends. 
Currently naloxone can only be supplied under prescription, but this requirement will 
be eased in October 2015 when a change to medicines regulations is expected to 
take effect. 
Regardless of how naloxone is provided locally, information on the risks of overdose 
and how to respond in an emergency should be available to all those at risk, their 
carers and families, and staff. 
What is naloxone? 
Naloxone is an emergency antidote to opiate overdose. It blocks opioid receptors to 
counteract the effects of opioid drugs (such as heroin, methadone and morphine), 
reversing the life-threatening effects of an overdose such as depressed breathing. 
Naloxone itself has no psychoactive properties and “no intoxicating effects or misuse 
potential”.1 It is injected directly into the body so is quick to take effect. 
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In ‘take-home naloxone’ programmes, suitable naloxone products, information, 
advice and training are provided to people who use drugs and to others. Such 
programmes can include the training of families, carers and peers to enable them to 
respond in the event of an overdose emergency, including the use of any available 
naloxone. 
Naloxone is currently available in ampoules, pre-filled syringes and a two-piece 
ampoule and syringe (called a Minijet®), and in concentrations of 400 micrograms 
(0.4mg) per ml or 1mg per ml. Pre-filled syringes and Minijets are simpler for 
emergency use by non-medics. 
Only Martindale’s Prenoxad® product is licensed specifically for use in the 
community but other naloxone products may be suitable depending on local and 
individual circumstances (eg, tailored information and training on those products has 
been provided). 
Naloxone has great potential for saving lives but, like most medicines, it can be 
harmful in some circumstances. Its use can induce rapid onset of withdrawal 
symptoms, such as nausea, vomiting and sweating. In a small number of cases, 
severe but short-term complications have been reported, including cardiac problems 
and risk of death.3 A relatively low first dose of naloxone (typically 400mcg) will have 
a treatment effect but reduce the risks. Additional low naloxone doses can then be 
given for as long as needed to achieve and maintain its overdose blocking effects. 
Despite this important caution on how to use naloxone in an emergency, there is 
clear guidance that the risk-benefit balance is “strongly in favour of naloxone 
distribution, due to its clear potential for saving lives”.2 
Current position in England 
There were 765 deaths registered in England and Wales in 2013 in which heroin or 
morphine were mentioned on the death certificate: an average of more than two 
every day, and a significant increase of 32% compared to those registered in 2012.4 
Naloxone is a prescription-only medicine and must be prescribed directly to a named 
patient (ie, someone who uses, or has used, opiates and is at risk of overdose), or 
supplied to an individual by means of a patient specific direction (PSD)a or a patient 
group direction (PGD). However, due to the nature of opiate overdose, naloxone is 
unlikely to be self-administered when needed. In 2005, naloxone was added to the 
list of injectable medicines that may be legally used by anyone for the purpose of 
saving a life in an emergency.5 It may therefore be usefully held by a third party such 
as a family member or carer. 
                                            
 
a
 PSDs are group prescriptions where each individual must be named on the documentation – as a result, they have rarely been used for 
take-home naloxone programmes. 
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Many services are currently using PGDs to provide take-home naloxone. PGDs are 
written instructions for the supply of prescription-only medicines to specified groups 
of patients without them being named in individual prescriptions.6 According to a 
recent survey in England by Release and the National Needle Exchange Forum, 
one-third of local authorities are currently providing take-home naloxone to people 
who use drugs, as part of their efforts to prevent overdose deaths.7 
Evidence and recommendations for take-home naloxone   
In 2010 the National Treatment Agency for Substance Misuse (NTA) helped 16 pilot 
sites across England to train the carers and relations of opiate misusers to respond 
to drug overdoses and use naloxone.8 The project concluded that “while training 
carers is beneficial in itself, training service users and providing overdose training 
and naloxone to as many people as possible may need to be considered to achieve 
a wider impact on overall fatal and non-fatal overdose rates.” 
The ACMD’s 2012 report ‘Consideration of naloxone’ reviewed naloxone availability 
and concluded with the following recommendations for government:  
 naloxone should be made more widely available, to tackle the high numbers of 
fatal opioid overdoses in the UK 
 government should ease the restrictions on who can be supplied with 
naloxone 
 government should investigate how people supplied with naloxone can be 
suitably trained to administer it in an emergency and respond to overdoses 
A 2013 study found that distribution of naloxone to heroin users is cost-effective, 
“even under markedly conservative assumptions”.9 
Evaluation of the take-home naloxone programme for people being released from 
Scottish prisons demonstrated significantly reduced deaths in this group.10 
World Health Organization (WHO) 2014 guidelines on ‘Community management of 
opioid overdose’ recommend that access to naloxone includes “people likely to 
witness an overdose in their community, such as friends, family members, partners 
of people who use drugs, and social workers.” 
Future developments 
The responses to a public consultation undertaken by the Medicines and Healthcare 
products Regulatory Agency (MHRA) in 2014 were largely supportive of the ACMD’s 
recommendations that naloxone be made more widely available, and the MHRA is 
drafting regulations to that end. 
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The legislative change expected to come into force in October 2015 is likely to mean 
that – similar to Water for Injections – naloxone is made exempt from prescription 
only medicine requirements when it is supplied by a drug service commissioned by a 
local authority or NHS. It may then be supplied to any individual needing access to 
naloxone, which could be: 
 someone who is using or has previously used opiates (illicit or prescribed) and 
is at potential risk of overdose 
 a carer, family member or friend liable to be on hand in case of overdose 
 a named individual in a hostel (or other facility where drug users gather and 
might be at risk of overdose), which could be a manager or other staff 
In all cases: 
 supply is on the grounds that it for the purpose of making naloxone available 
for saving a life in an emergency 
 there will be no need for the usual Prescription Only Medicine requirements, 
just a requirement that the supply is suitably recorded 
There is some interest in nasal delivery of naloxone but a suitable product has not 
been licensed for use. However, a non-injectable product would likely not need to be 
prescription-only and could be easier for non-medical staff to administer. 
Common myths about naloxone 
“It can be abused” 
Naloxone has no psychoactive properties and so no direct misuse potential.1  
“It encourages overdose or risky behaviours” 
Surveys of people who use opiates suggest this is not the case.11 As naloxone works 
by inducing rapid withdrawal from opioid drugs, its use is likely to be something that 
people who use these drugs are keen to avoid. Take-home naloxone should always 
be provided alongside training on preventing and avoiding overdose, and efforts to 
raise awareness of risk behaviours and harm reduction solutions. 
“It is difficult to administer” 
Administering naloxone in the community is as easy as ABC(N) – 
see box. It is important first to call an ambulance, check the person 
is breathing and put them in the recovery position. Then simply 
attach a needle (if not already fitted) to a pre-filled syringe or 
MiniJet® and inject the overdosed person in a large muscle (thigh, 
buttock or top of the arm). There is a simple video at 
Ambulance 
Breathing 
ReCovery position 
Naloxone 
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www.harmreductionworks.org.uk/2_films/overdose_and_naloxone.html. It can be 
ordered on DVD at www.harmreductionworks.org.uk/6_booklets/overdose.html 
In 2009, the NTA piloted a naloxone programme for families and carers, which 
demonstrated how these individuals were able to deliver this lifesaving intervention. 
Nearly 500 people were trained, and naloxone was used at least 18 times in 
emergency situations.8 
The provision of naloxone should usually be accompanied by training in overdose 
prevention and management – though this does not need to be extensive.12 See the 
section on ‘What to cover in overdose and naloxone training’.  
“It is not cost effective” 
Research from the USA found that naloxone distribution “was cost-effective in all 
deterministic and probabilistic sensitivity and scenario analyses, and it was cost-
saving if it resulted in fewer overdoses or emergency medical service activations”.9 
“It is contradictory to a recovery focus” 
Take-home naloxone is a safeguard for people still using opiate drugs (including 
those on opioid substitution treatment) and those currently abstinent who are at risk 
of relapse and overdose, including those leaving prison or treatment services. 
“We need to wait until October 2015” 
In October 2015, legislation is expected to be enacted that will allow wider access to 
naloxone. But this should not delay the provision of take-home naloxone to at-risk 
individuals now, using existing provision for prescriptions and PGDs as outlined on 
page 2. 
 
Birmingham: a case study in how to introduce take-home naloxone 
In 2012, the clinical leads for Birmingham’s drug treatment services decided to 
offer overdose training and take-home naloxone as part of normal service 
provision across the city – building on the NTA pilot schemes and the national 
programme in Scotland. To date, they have provided training and naloxone to 
more than 2,000 people through a PGD. No additional funding was obtained – the 
costs of naloxone make up just a small fraction of the overall prescribing costs for 
services. All staff and selected peer trainers received training on the use of 
naloxone, and this has become part of normal keywork. Training of individuals 
takes only 10-20 minutes during one-to-one keyworking sessions before naloxone 
is dispensed. 
A representative of each service attends ‘naloxone steering group’ meetings each 
month. Records capture the number of kits dispensed and the reported use of 
naloxone in emergencies.  
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Introducing take-home naloxone 
Based on Birmingham’s experience, useful steps may include: 
1. Identify local naloxone champions – this may be you  
2. Organise an initial ‘informing the managers’ or ‘training the trainers’ session 
3. Consider who will receive naloxone supplies and how: users and carers, 
hostels and pharmacies, etc 
4. Consider who will pay for naloxone supplies from different locations 
5. Agree how you will re-supply people when naloxone is used or expires, and 
who will pay. Will you have a system that flags approaching expiry dates to 
keyworkers/pharmacies/etc? 
6. Hold regular meetings for local naloxone champions – including people who 
use drugs – to encourage progress, discuss any barriers or concerns, and 
learn from each other 
7. Explore the products and prices available, speaking to local pharmaceutical 
representative(s), and decide together with local service providers which to 
purchase 
8. Complete the paperwork and processes for a PGD, working with the local 
clinical commissioning group(s) and director of public health as appropriate 
9. Inform and liaise with the police, local coroners, ambulance service clinical 
lead, hostel managers and pharmacies  
10. Purchase the naloxone kits, and make the necessary arrangements for 
stocking and distributing them, and for re-supply when naloxone held by an 
individual has been used or expires 
11. Provide training to all drug keyworkers, all opioid substitution treatment (OST) 
prescribers locally, dispensing pharmacists, and local service user groups – all 
of whom can contribute to the onward dissemination of information 
12. Arrange for training to be provided to people who use drugs, patients and 
clients, and their families and friends (see next section). Consider who is best 
positioned to deliver this training. Offer training to as many people as possible 
13. Consider whether and how you will record the numbers of kits dispensed and 
the reported number of times that naloxone has been used to reverse 
overdoses 
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What to cover in overdose and naloxone training 
The provision of naloxone should usually be accompanied by training in overdose 
prevention and management. This does not need to be complex or long but should 
highlight the need for individuals to seek medical attention even if naloxone has been 
administered, because of its relatively short duration of action. 
Training will usually cover: 
 overdose risks: polydrug (especially 
benzodiazepines) and alcohol use, getting 
older, post-detox/rehab/prison 
 what naloxone can and can’t do: it just 
reverses opiate overdose. If someone has also 
taken too many other drugs or too much 
alcohol, it won’t reverse their effects 
 how to identify an opiate overdose – lack of 
consciousness, shallow or no breathing, 
‘snoring’, and blueing of the lips and fingertips 
 steps to take in responding to an overdose* 
 how to use naloxone, including addressing any 
fears about needles and injecting 
 how to get naloxone replaced when it has 
either been used or is approaching its expiry 
date  
Recording 
Local areas and their services will want to make suitable arrangements to record the 
supply of naloxone for the following purposes: 
 to demonstrate that supply has been made appropriately for use in emergency 
 to monitor who has received training and naloxone supplies, and ensure 
equitable provision to different groups 
 to understand when and how naloxone is used in overdose situations and to 
arrange re-supply when naloxone has been used or is approaching expiry 
 for contract and performance management 
  
*Having identified an overdose: 
1. Call an ambulance  
2. Give rescue breaths if the 
person is not breathing 
3. Put them in the recovery 
position 
4. Inject the initial 
recommended small 
amount of naloxone 
(usually 400mcg), wait 
(about 1 minute).  If 
unresponsive, inject 
another small amount. 
Repeat as necessary 
5. Stay with the person at 
least until the ambulance 
arrives 
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Naloxone-alone is not enough 
Naloxone is just one way to try to reduce drug-related deaths. A whole package of 
measures needs to be considered to prevent overdoses and other causes of drug-
related deaths. 
As part of a comprehensive programme of work to reduce the transmission of blood-
borne viruses and to prevent DRDs PHE: 
 published a Turning Evidence into Practice briefing on preventing drug-related 
deaths 
 continues to support the implementation of NICE’s updated guidelines on 
needle and syringe programmes 
 convened a national summit on DRDs in partnership with DrugScope and the 
Local Government Association 
 convenes regular meetings of a national intelligence network on drug-related 
health harms which maintains a focus on DRDs 
Resources 
 The ACMD’s ‘Consideration of naloxone’: 
www.gov.uk/government/uploads/system/uploads/attachment_data/file/11912
0/consideration-of-naloxone.pdf 
 The Scottish Drugs Forum’s www.naloxone.org.uk, which has lots of 
resources itself 
 The NTA’s report on its overdose and naloxone training programme for 
families and carers: www.nta.nhs.uk/naloxone-report-2011.aspx 
 Harm Reduction Works overdose and naloxone DVD (HRDVD6N): 
www.harmreductionworks.org.uk/6_booklets/overdose.html 
 The World Health Organization’s 2014 guidelines on ‘Community management 
of opioid overdose’: 
www.who.int/substance_abuse/publications/management_opioid_overdose 
 SMMGP’s e-learning, ‘Naloxone saves lives’: www.smmgp-elearning.org.uk 
 An international website supporting naloxone distribution with free resources: 
www.naloxoneinfo.org 
Produced with the help of the National Needle Exchange Forum: www.nnef.org.uk 
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